News Headlines

  1. Update On Phase III Clinical Trials Of Lanabecestat For Alzheimer’s Disease

    AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer’s disease.

  2. Vical Reports Phase 2 Trial Of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint

    Vical Incorporated (Nasdaq:VICL) today announced top-line results from a randomized, double-blind, placebo-controlled, Phase 2 clinical study of its therapeutic bivalent vaccine candidate for herpes simplex virus type 2 (HSV-2), the leading cause of recurrent genital herpes.

  3. International Stem Cell Corporation Doses First Patient Of The Third Cohort In Parkinson's Disease Clinical Trial

    International Stem Cell Corporation (OTCQB:ISCO) ( ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that the first patient of the third cohort of the clinical trial for Parkinson's disease was successfully transplanted with 70,000,000 ISC-hpNSC®.

  4. CRF Health Industry Luminaries To Share eSource Expertise In Clinical Trials At DIA 2018

    CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, recently announced that it will host a series of interactive workshops and speaker sessions at DIA’s 2018 Global Annual Meeting, June 24-28, Boston, MA.

  5. MMS Promotes Two Leaders At Its Asia Headquarters Amid Strong Growth Period

    MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced recently two major promotions at its Asia headquarters, including Dr. Arunima Sen has been promoted to the position of Head, Drug Safety and Medical Writing in India, and Nandini Vijaisimha has been promoted to the position of Head, HR and Administration in India.

  6. Bracket Appoints James Jay As Senior Vice President, Endpoint Solutions To Drive Continued Growth Of Its Technology And Service Offerings

    Bracket, a leading clinical trial technology and specialty services provider, recently announced James Jay has joined the Company as Senior Vice President, Endpoint Solutions, reporting to Bracket’s Chief Executive Officer, Mike Nolte. 

  7. Protalix BioTherapeutics Announces Additional Positive Results From Final Analysis Of The Phase II Clinical Trial Of OPRX-106 For The Treatment Of Ulcerative Colitis

    Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today that additional positive results from the Company’s phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis (UC) were presented at the Digestive Disease Week®(DDW) 2018 Annual Meeting.

  8. TESARO Announces Collaboration To Evaluate ZEJULA® In Combination With Anti-PD-L1 Cancer Immunotherapy And MEK Inhibitor In Platinum-Sensitive Ovarian Cancer

    TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ®), the MEK inhibitor cobimetinib (COTELLIC®) and TESARO’s PARP inhibitor ZEJULA® (niraparib) in patients with platinum-sensitive ovarian cancer.

  9. Endocyte Announces Enrollment Of First Patient In Phase 3 VISION Trial Of 177Lu-PSMA-617 In Prostate Cancer

    Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE, a member of Precision Cancer Research.

  10. RedHill Biopharma Announces New U.S. Patent For Its Experimental Ebola Therapy

    RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering RedHill’s proprietary experimental therapy for the treatment of Ebola virus disease. The patent is expected to be valid until 2035.